Observational studyCJEM2026
Safety profile of midazolam for minimal sedation in the pediatric emergency department.
Observational study in CJEM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough minimal sedation with midazolam is frequently performed in the pediatric emergency department (ED) for various procedures, limited research exists regarding its safety profile, and no clear guidelines define the resources required for minimal sedation. The main objective of this study was to determine the proportion of children who developed adverse events after receiving oral or intranasal midazolam for minimal sedation in our pediatric ED.
methodsWe conducted an observational, single center study including all children who presented to the pediatric ED between January 1, 2015, and December 31, 2021, and underwent minimal sedation with oral or intranasal midazolam.
resultsA total of 2544 children with a median age of 4 years (IQR 2-6 years) were included. We identified a total of 12 (0.47%) adverse events: 9 (0.35%) minimal, 2 (0.08%) minor, and 1 (0.04%) moderate. There were no sentinel adverse events. All children were discharged home from the pediatric ED, and none required hospitalization.
conclusionThe incidence of adverse events during minimal sedation with oral or intranasal midazolam in our pediatric ED was low, and interventions were rarely required. Minimal sedation with oral or intranasal midazolam appears to be a safe and well-tolerated procedure. Our findings support the safety of minimal sedation with midazolam in a structured, well-monitored ED setting.
Indexed as
Identifiers
41524826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.